Abstract 31P
Background
Breast edema is defined as a high signal intensity on T2-weighted magnetic resonance imaging (MRI), and it is an essential image phenotype of breast MRI. The purpose of this study was to investigate the prognostic implication of breast edema on preoperative breast MRI in breast cancer patients.
Methods
We retrospectively analyzed the data of 899 breast cancer patients at a single institution. Patients were divided into the edema-positive group (EPG) and the edema-negative group (ENG) according to the presence of breast edema on preoperative breast MRI. We compared the clinicopathologic characteristics and the survival outcomes between the two groups. A two-sample t-test was used to determine statistical differences between mean ages, and Pearson’s χ2 test was used to determine statistical differences between all the other baseline characteristics. The log-rank test was used to compare the survival curves from Kaplan–Meier estimator. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and 95% confidence interval (CI).
Results
There were 399 (44.4%) patients in the EPG and 500 (55.6%) patients in the ENG. Among patients in the EPG, peritumoral, prepectoral, and subcutaneous edemas were present in 387, 130, and 66 patients, respectively. EPG showed significantly higher rates of axillary lymph node metastasis (55.6% vs. 19.2%, p < 0.001) and lymphovascular invasion (LVI) (57.9% vs. 12.6%, p < 0.001) than ENG. Patients in the EPG showed significantly worse overall survival rate (log-rank p < 0.001; HR: 4.83; 95% CI: 2.56-9.11) and recurrence-free survival rate (log-rank p < 0.001; HR: 3.00; 95% CI: 1.94-4.63) than those in the ENG. After adjusting for other variables, breast edema still remained a significant factor affecting overall survival rate regardless of edema type.
Conclusions
Breast edema on preoperative breast MRI is strongly correlated with several clinicopathological features including nodal metastasis and LVI in breast cancer patients. It significantly affects the survival rate and disease recurrence of breast cancer patients. Therefore, detailed descriptions of breast edema in preoperative breast MRI may provide prognosis prediction and more intensive surveillance is needed for breast cancer patients with breast edema.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
271P - Prostate cancer with histone modifier UTX mutations can benefit from olaparib
Presenter: NOBUHITO MURAMOTO
Session: Poster Display
Resources:
Abstract
272P - Comparison between MRI-targeted and standard biopsy for prostate cancer detection: A systematic review and meta-analysis
Presenter: Andree Kurniawan
Session: Poster Display
Resources:
Abstract
273P - The diagnostic performance of cognitive MRI-targeted biopsy in biopsy-naïve patients undergoing systematic 14-region 18-core biopsy: Do the three areas affect the results?
Presenter: Yuka Toyama
Session: Poster Display
Resources:
Abstract
274P - Index tumor location influencing early biochemical recurrence after radical prostatectomy in patients with negative surgical margins
Presenter: Jun Akatsuka
Session: Poster Display
Resources:
Abstract
275P - Prognosis of metastatic castration-resistant prostate cancer in response to chemotherapy and PSMA expression in circulating tumor cells
Presenter: Naoya Nagaya
Session: Poster Display
Resources:
Abstract
276P - Prognostic significance of p53 mutation in metastatic hormone-sensitive prostate cancer
Presenter: Lakshmi Kamala
Session: Poster Display
Resources:
Abstract
277P - Vasohibin-1 expression as a biomarker of aggressive growth in prostate ductal adenocarcinoma
Presenter: Murad Salomov
Session: Poster Display
Resources:
Abstract
278P - Full-coverage radiotherapy for prostate cancer patients with oligometastases
Presenter: Bichun Xu
Session: Poster Display
Resources:
Abstract
279P - Hypofractionated radiotherapy protocol implementation and early outcomes for prostate cancer patients: A single institution retrospective review
Presenter: Thu Nguyen
Session: Poster Display
Resources:
Abstract
280P - Radium-223 for patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases progressing after first-line abiraterone or enzalutamide: One institutional experience
Presenter: Keng Man Chiang
Session: Poster Display
Resources:
Abstract